Navigation Links
Enigma Diagnostics Announces Patent On Real-Time Monitoring of Amplification Reactions Upheld In Entirety Following Opposition From BD at European Patent Office
Date:6/16/2009

PORTON DOWN, England, June 16 /PRNewswire/ -- Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today it was issued European Patent EP1044283, which covers the use of endonuclease-based reporting in PCR and other nucleic acid amplification technologies. Becton, Dickinson and Company (BD) had filed a claim in opposition to this patent which was rejected by the European Patent Office at a proceeding in Munich on May 28.

The patent is part of a substantial portfolio of intellectual property exclusively licensed to Enigma Diagnostics by the Secretary of State for Defence. The technology involves the use of a thermostable endonuclease to cut a probe that recognises a specific sequence in the target amplification product. The system may be applied to a wide variety of molecular diagnostic applications including the rapid detection of viral and bacterial pathogens.

Enigma Diagnostics has developed products that completely automate the PCR process including sample extraction, amplification and analysis for application at the point-of-care by non-laboratory operators.

John McKinley, CEO of Enigma Diagnostics, stated: "The maintenance of this key patent secures and supports the further development of Enigma's intellectual property portfolio."

    Contacts

    UK Contact:
    Enigma Diagnostics
    Deborah Cordingley
    deborah.cordingley@enigmadiagnostics.com
    +44 1980 590131

    US Contact:
    Richard Lewis Communications, Inc.
    212-827-0020
    Gregory Tiberend - Media
    gtiberend@rlcinc.com
    Cecelia Heer - Investors
    cheer@rlcinc.com

About Enigma Diagnostics Limited

Enigma Diagnostics Limited is a private UK based company specialising in developing the next generation of rapid molecular diagnostic instrument platforms for decentralised and point-of-care settings.

Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for field-based, decentralised and point-of-care tests providing results from a raw sample in less than 45 minutes.

The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high value Applied Markets. Enigma's commercialisation strategy is to maximise revenues from a continuous flow of market leading rapid diagnostic point-of-care and in-field instrument and assay platforms, derived from its broad Intellectual Property portfolio of issued and filed patents. Enigma will partner with market leaders where global penetration of markets is required and where appropriate will build an in-house sales and marketing capability to direct distribution of its products.

Enigma has an exclusive licence from the Defence Science and Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded research and has licences from Applied Biosystems and Celera Licences for the commercialisation of real-time PCR instruments. Enigma's R&D activities have generated a portfolio of over 50 plus worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including US, EU and Japan with more extensive filing and grants across a number of other key territories.

For more information visit www.enigmadiagnostics.com


'/>"/>
SOURCE Enigma Diagnostics Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New light shed on the enigma of salt intake and hypertension
2. The Marketing Enigma
3. Enigma Diagnostics Announces a Signed Term Sheet for Patent Licenses with Roche Molecular Systems, Inc.
4. Quest Diagnostics to Speak at the Jefferies 3rd Annual Healthcare Conference
5. Quest Diagnostics Announces Pricing of Tender Offer for Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes
6. Quest Diagnostics to Speak at the William Blair & Company 29th Annual Growth Stock Conference
7. Quest Diagnostics India Recognized as Laureate by the Computerworld Honors Program
8. Quest Diagnostics Announces Early Tender Results of Offer to Purchase Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes
9. Quest Diagnostics HemoCue AB Subsidiary to Add Avie(TM) Hemoglobin A1c to Diabetes Point-of-Care Test Suite
10. Rules-Based Medicine, Inc. Names Tony Barnes to Lead Expanding Diagnostics Business
11. Quest Diagnostics Introduces First Comprehensive Laboratory Test To Analyze KRAS, NRAS, and BRAF Gene Mutations in Reflex Testing Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... From ... American Academy of Dermatology Annual Meeting at the Walter E. Washington Convention Center ... awareness for both the condition of hyperhidrosis (excessive sweating) and its treatment options. ...
(Date:2/11/2016)... ... February 11, 2016 , ... Food Labeling ... in health and wellness best practices in the past couple of decades, and ... is American Heart Month, which acts as an exceptional opportunity to revise food ...
(Date:2/11/2016)... ... ... As part of their 2015 end of year funding strategy, Colleen’s ... gifted $10,000 to University of Chicago to support ovarian cancer research being conducted by ... honored to support a promising young investigator from Dr. Lengyel’s lab at the University ...
(Date:2/10/2016)... ... 10, 2016 , ... Sherly Sulaiman, certified clinical hypnotherapist and ... sessions to help Los Angeles-area actors cope with rejection, improve their auditions, and ... as “Mindfulness for Actors and Artists,” has been featured in Daily Actor ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... care communications company offering education, research and medical media, has launched ... working in infectious diseases. , As the all-inclusive resource for infectious disease ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... 2016 North America , ... MarketsandMarkets, The global market is expected to reach USD 20,190.1 Million ... CAGR of 10.2%. --> North America , ... by MarketsandMarkets, The global market is expected to reach USD 20,190.1 ... a CAGR of 10.2%. --> According to a new ...
(Date:2/10/2016)... SINGAPORE , Feb. 11, 2016  QT Vascular ... "QT Vascular", and together with its subsidiaries, the ... its ongoing litigation with AngioScore, Inc. ("ÄngioScore") (now ... the United States ... (the "Federal Circuit") reversed an earlier district court ...
(Date:2/10/2016)... PITTSBURGH , 10 februari ... och detta pressmeddelande får inte distribueras, vare ... och inga anmälningssedlar kommer att accepteras från ... land där Erbjudandet, distribution av detta pressmeddelande ... strida mot tillämpliga lagar eller regler eller ...
Breaking Medicine Technology: